Literature DB >> 19657442

Continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes: Do the benefits outweigh the risks?

Gillian H Toth1.   

Abstract

Intensive management of diabetes is the gold standard in the treatment of children with type 1 diabetes. Novel insulin delivery techniques have been developed to improve the ability to administer multiple daily doses of insulin. Continuous subcutaneous insulin infusion (CSII) is a method of insulin delivery that is increasing in popularity. The present article reviews the risks and benefits of CSII in children. At this time, there is limited quality published evidence to make a definitive claim about the potential risks and benefits of CSII in children. The risk of diabetic ketoacidosis and individual family factors must be considered before initiation of treatment.

Entities:  

Keywords:  Continuous subcutaneous insulin infusion; Intensive diabetes management; Risks and benefits; Type 1 diabetes

Year:  2005        PMID： 19657442      PMCID： PMC2720898          DOI： 10.1093/pch/10.1.28

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN： 1205-7088            Impact factor:   2.253


  12 in total

1.  Treatment issues in type 1 diabetes.

Authors:  Zachary T Bloomgarden
Journal:  Diabetes Care       Date:  2002-01       Impact factor: 19.112

2.  Continuous subcutaneous insulin infusion.

Authors: 
Journal:  Diabetes Care       Date:  2003-01       Impact factor: 19.112

3.  Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes.

Authors:  B W Bode; R D Steed; P C Davidson
Journal:  Diabetes Care       Date:  1996-04       Impact factor: 19.112

4.  Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials.

Authors:  John Pickup; Martin Mattock; Sally Kerry
Journal:  BMJ       Date:  2002-03-23

5.  Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus.

Authors:  Jean Litton; Alan Rice; Nancy Friedman; Jon Oden; Mary M Lee; Michael Freemark
Journal:  J Pediatr       Date:  2002-10       Impact factor: 4.406

6.  Insulin pump therapy: a meta-analysis.

Authors:  Jill Weissberg-Benchell; Jeanne Antisdel-Lomaglio; Roopa Seshadri
Journal:  Diabetes Care       Date:  2003-04       Impact factor: 19.112

7.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

8.  Continuous subcutaneous insulin infusion pump treatment in children with type 1 diabetes mellitus.

Authors:  Raphael Liberatore; Kusiel Perlman; Jennifer Buccino; Ana Artiles-Sisk; Denis Daneman
Journal:  J Pediatr Endocrinol Metab       Date:  2004-02       Impact factor: 1.634

9.  Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial.

Authors:  Naomi Weintrob; Hadassa Benzaquen; Avinoam Galatzer; Shlomit Shalitin; Liora Lazar; Gila Fayman; Pearl Lilos; Zvi Dickerman; Moshe Phillip
Journal:  Pediatrics       Date:  2003-09       Impact factor: 7.124

10.  A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine.

Authors:  Elizabeth A Doyle; Stuart A Weinzimer; Amy T Steffen; Jo Ann H Ahern; Miranda Vincent; William V Tamborlane
Journal:  Diabetes Care       Date:  2004-07       Impact factor: 19.112
View more
  1 in total

1.  Use of continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes mellitus: a systematic mapping review.

Authors:  Carolina Spinelli Alvarenga; Rebecca Ortiz La Banca; Rhyquelle Rhibna Neris; Valéria de Cássia Sparapani; Miguel Fuentealba-Torres; Denisse Cartagena-Ramos; Camila Lima Leal; Marcos Venicio Esper; Lucila Castanheira Nascimento
Journal:  BMC Endocr Disord       Date:  2022-02-19       Impact factor: 2.763
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.